\BOOKMARK [1][-]{section.1}{Open Source Value Project}{}% 1
\BOOKMARK [1][-]{section.2}{Topic definition}{}% 2
\BOOKMARK [1][-]{section.3}{Purpose}{}% 3
\BOOKMARK [2][-]{subsection.3.1}{Value assessment}{section.3}% 4
\BOOKMARK [2][-]{subsection.3.2}{Evaluation of scientific uncertainty}{section.3}% 5
\BOOKMARK [1][-]{section.4}{Iterative process}{}% 6
\BOOKMARK [1][-]{section.5}{Components}{}% 7
\BOOKMARK [1][-]{section.6}{Model structure}{}% 8
\BOOKMARK [2][-]{subsection.6.1}{Disease model}{section.6}% 9
\BOOKMARK [2][-]{subsection.6.2}{Adverse events}{section.6}% 10
\BOOKMARK [2][-]{subsection.6.3}{Cost and utility}{section.6}% 11
\BOOKMARK [2][-]{subsection.6.4}{Patient heterogeneity}{section.6}% 12
\BOOKMARK [2][-]{subsection.6.5}{Rationale for individual-level simulation}{section.6}% 13
\BOOKMARK [1][-]{section.7}{Model outcomes}{}% 14
\BOOKMARK [2][-]{subsection.7.1}{Health outcomes}{section.7}% 15
\BOOKMARK [2][-]{subsection.7.2}{Risks}{section.7}% 16
\BOOKMARK [2][-]{subsection.7.3}{Costs}{section.7}% 17
\BOOKMARK [2][-]{subsection.7.4}{Value assessment}{section.7}% 18
\BOOKMARK [1][-]{section.8}{Source data and parameter estimation}{}% 19
\BOOKMARK [2][-]{subsection.8.1}{Treatment effects for transition rates}{section.8}% 20
\BOOKMARK [3][-]{subsubsection.8.1.1}{Relative treatment effects with 1L therapy}{subsection.8.1}% 21
\BOOKMARK [4][-]{subsubsubsection.8.1.1.1}{Network meta-analysis model}{subsubsection.8.1.1}% 22
\BOOKMARK [4][-]{subsubsubsection.8.1.1.2}{Likelihood}{subsubsection.8.1.1}% 23
\BOOKMARK [4][-]{subsubsubsection.8.1.1.3}{Prior distributions}{subsubsection.8.1.1}% 24
\BOOKMARK [4][-]{subsubsubsection.8.1.1.4}{Model selection}{subsubsection.8.1.1}% 25
\BOOKMARK [4][-]{subsubsubsection.8.1.1.5}{Estimated time-varying hazard ratios}{subsubsection.8.1.1}% 26
\BOOKMARK [3][-]{subsubsection.8.1.2}{Absolute effects with 1L reference treatment}{subsection.8.1}% 27
\BOOKMARK [3][-]{subsubsection.8.1.3}{Absolute effects with 2L therapy}{subsection.8.1}% 28
\BOOKMARK [3][-]{subsubsection.8.1.4}{Software}{subsection.8.1}% 29
\BOOKMARK [3][-]{subsubsection.8.1.5}{Use of meta-analysis results in economic model}{subsection.8.1}% 30
\BOOKMARK [2][-]{subsection.8.2}{Adverse events}{section.8}% 31
\BOOKMARK [2][-]{subsection.8.3}{Utilities}{section.8}% 32
\BOOKMARK [2][-]{subsection.8.4}{Health care sector costs}{section.8}% 33
\BOOKMARK [3][-]{subsubsection.8.4.1}{Treatment costs}{subsection.8.4}% 34
\BOOKMARK [3][-]{subsubsection.8.4.2}{Inpatient and outpatient costs}{subsection.8.4}% 35
\BOOKMARK [3][-]{subsubsection.8.4.3}{Adverse event costs}{subsection.8.4}% 36
\BOOKMARK [2][-]{subsection.8.5}{Productivity}{section.8}% 37
\BOOKMARK [2][-]{subsection.8.6}{Value of hope}{section.8}% 38
\BOOKMARK [1][-]{section.9}{Simulation and uncertainty analysis}{}% 39
\BOOKMARK [2][-]{subsection.9.1}{Parameter uncertainty}{section.9}% 40
\BOOKMARK [2][-]{subsection.9.2}{Structural uncertainty}{section.9}% 41
\BOOKMARK [2][-]{subsection.9.3}{Implementation}{section.9}% 42
\BOOKMARK [1][-]{section*.34}{Appendices}{}% 43
\BOOKMARK [1][-]{Appendix.1.A}{Systematic Literature Review}{}% 44
\BOOKMARK [2][-]{subsection.1.A.1}{Treatment effects for transition rates}{Appendix.1.A}% 45
\BOOKMARK [2][-]{subsection.1.A.2}{Utilities}{Appendix.1.A}% 46
\BOOKMARK [2][-]{subsection.1.A.3}{Resource use, productivity, and cost}{Appendix.1.A}% 47
\BOOKMARK [2][-]{subsection.1.A.4}{Study identification}{Appendix.1.A}% 48
\BOOKMARK [2][-]{subsection.1.A.5}{Study selection}{Appendix.1.A}% 49
\BOOKMARK [2][-]{subsection.1.A.6}{Data collection}{Appendix.1.A}% 50
\BOOKMARK [2][-]{subsection.1.A.7}{Limitations}{Appendix.1.A}% 51
\BOOKMARK [2][-]{subsection.1.A.8}{Kaplan-Meier curves}{Appendix.1.A}% 52
\BOOKMARK [1][-]{References.1}{References}{}% 53
